Interim safety analysis of cancer immunotherapy trials Network – 12 (CITN-12): a Phase 1 study of pembrolizumab in patients with HIV and cancer
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2017-12-01
|
| Series: | Journal of Virus Eradication |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2055664020305677 |
| _version_ | 1818610857465085952 |
|---|---|
| author | T.S. Uldrick M.A. ‘Mac’ Cheever P.H. Gonçalves S. Fling K. Aleman B. Emu M.S. Ernstoff R. Gorelick J. Kaiser H. E Kohrt A. Lacroix M. Lindsley L. M Lundgren K. Lurain F. Maldarelli C. Parsons E. Sharon A. Widell R. Yarchoan |
| author_facet | T.S. Uldrick M.A. ‘Mac’ Cheever P.H. Gonçalves S. Fling K. Aleman B. Emu M.S. Ernstoff R. Gorelick J. Kaiser H. E Kohrt A. Lacroix M. Lindsley L. M Lundgren K. Lurain F. Maldarelli C. Parsons E. Sharon A. Widell R. Yarchoan |
| author_sort | T.S. Uldrick |
| collection | DOAJ |
| first_indexed | 2024-12-16T15:21:06Z |
| format | Article |
| id | doaj.art-34dd060a81db44149080d1fab5727d04 |
| institution | Directory Open Access Journal |
| issn | 2055-6640 |
| language | English |
| last_indexed | 2024-12-16T15:21:06Z |
| publishDate | 2017-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Virus Eradication |
| spelling | doaj.art-34dd060a81db44149080d1fab5727d042022-12-21T22:26:38ZengElsevierJournal of Virus Eradication2055-66402017-12-0135556Interim safety analysis of cancer immunotherapy trials Network – 12 (CITN-12): a Phase 1 study of pembrolizumab in patients with HIV and cancerT.S. Uldrick0M.A. ‘Mac’ Cheever1P.H. Gonçalves2S. Fling3K. Aleman4B. Emu5M.S. Ernstoff6R. Gorelick7J. Kaiser8H. E Kohrt9A. Lacroix10M. Lindsley11L. M Lundgren12K. Lurain13F. Maldarelli14C. Parsons15E. Sharon16A. Widell17R. Yarchoan18National Cancer Institute, HIV and AIDS Malignancy Branch, Bethesda, MD, USACancer Immunotherapy Trials Network/Fred Hutchinson Cancer Res Center, Seattle, WA, USANational Cancer Institute, HIV and AIDS Malignancy Branch, Bethesda, MD, USACancer Immunotherapy Trials Network/Fred Hutchinson Cancer Res Center, Seattle, WA, USANational Cancer Institute, HIV and AIDS Malignancy Branch, Bethesda, MD, USAYale University, Medicine/Oncology, New Haven, CN, USARoswell Park Cancer Institute, Buffalo, NY, USANational Cancer Institute at Frederick, AIDS and Cancer Virus Program, Frederick, MD, USACancer Immunotherapy Trials Network/Fred Hutchinson Cancer Res Center, Seattle, WA, USAStanford University, Medicine/Oncology, Stanford, CA, USACancer Immunotherapy Trials Network/Fred Hutchinson Cancer Res Center, Seattle, WA, USANational Cancer Institute, HIV and AIDS Malignancy Branch, Bethesda, MD, USACancer Immunotherapy Trials Network/Fred Hutchinson Cancer Res Center, Seattle, WA, USANational Cancer Institute, HIV and AIDS Malignancy Branch, Bethesda, MD, USANational Cancer Institute, HIV Dynamics and Replication Program, Frederick, MD, USALouisiana State University Health Science Center, New Orleans, LA, USANational Cancer Institute, Cancer Therapy and Evaluation Program, Bethesda, MD, USANational Cancer Institute, HIV and AIDS Malignancy Branch, Bethesda, MD, USANational Cancer Institute, HIV and AIDS Malignancy Branch, Bethesda, MD, USAhttp://www.sciencedirect.com/science/article/pii/S2055664020305677 |
| spellingShingle | T.S. Uldrick M.A. ‘Mac’ Cheever P.H. Gonçalves S. Fling K. Aleman B. Emu M.S. Ernstoff R. Gorelick J. Kaiser H. E Kohrt A. Lacroix M. Lindsley L. M Lundgren K. Lurain F. Maldarelli C. Parsons E. Sharon A. Widell R. Yarchoan Interim safety analysis of cancer immunotherapy trials Network – 12 (CITN-12): a Phase 1 study of pembrolizumab in patients with HIV and cancer Journal of Virus Eradication |
| title | Interim safety analysis of cancer immunotherapy trials Network – 12 (CITN-12): a Phase 1 study of pembrolizumab in patients with HIV and cancer |
| title_full | Interim safety analysis of cancer immunotherapy trials Network – 12 (CITN-12): a Phase 1 study of pembrolizumab in patients with HIV and cancer |
| title_fullStr | Interim safety analysis of cancer immunotherapy trials Network – 12 (CITN-12): a Phase 1 study of pembrolizumab in patients with HIV and cancer |
| title_full_unstemmed | Interim safety analysis of cancer immunotherapy trials Network – 12 (CITN-12): a Phase 1 study of pembrolizumab in patients with HIV and cancer |
| title_short | Interim safety analysis of cancer immunotherapy trials Network – 12 (CITN-12): a Phase 1 study of pembrolizumab in patients with HIV and cancer |
| title_sort | interim safety analysis of cancer immunotherapy trials network 12 citn 12 a phase 1 study of pembrolizumab in patients with hiv and cancer |
| url | http://www.sciencedirect.com/science/article/pii/S2055664020305677 |
| work_keys_str_mv | AT tsuldrick interimsafetyanalysisofcancerimmunotherapytrialsnetwork12citn12aphase1studyofpembrolizumabinpatientswithhivandcancer AT mamaccheever interimsafetyanalysisofcancerimmunotherapytrialsnetwork12citn12aphase1studyofpembrolizumabinpatientswithhivandcancer AT phgoncalves interimsafetyanalysisofcancerimmunotherapytrialsnetwork12citn12aphase1studyofpembrolizumabinpatientswithhivandcancer AT sfling interimsafetyanalysisofcancerimmunotherapytrialsnetwork12citn12aphase1studyofpembrolizumabinpatientswithhivandcancer AT kaleman interimsafetyanalysisofcancerimmunotherapytrialsnetwork12citn12aphase1studyofpembrolizumabinpatientswithhivandcancer AT bemu interimsafetyanalysisofcancerimmunotherapytrialsnetwork12citn12aphase1studyofpembrolizumabinpatientswithhivandcancer AT msernstoff interimsafetyanalysisofcancerimmunotherapytrialsnetwork12citn12aphase1studyofpembrolizumabinpatientswithhivandcancer AT rgorelick interimsafetyanalysisofcancerimmunotherapytrialsnetwork12citn12aphase1studyofpembrolizumabinpatientswithhivandcancer AT jkaiser interimsafetyanalysisofcancerimmunotherapytrialsnetwork12citn12aphase1studyofpembrolizumabinpatientswithhivandcancer AT hekohrt interimsafetyanalysisofcancerimmunotherapytrialsnetwork12citn12aphase1studyofpembrolizumabinpatientswithhivandcancer AT alacroix interimsafetyanalysisofcancerimmunotherapytrialsnetwork12citn12aphase1studyofpembrolizumabinpatientswithhivandcancer AT mlindsley interimsafetyanalysisofcancerimmunotherapytrialsnetwork12citn12aphase1studyofpembrolizumabinpatientswithhivandcancer AT lmlundgren interimsafetyanalysisofcancerimmunotherapytrialsnetwork12citn12aphase1studyofpembrolizumabinpatientswithhivandcancer AT klurain interimsafetyanalysisofcancerimmunotherapytrialsnetwork12citn12aphase1studyofpembrolizumabinpatientswithhivandcancer AT fmaldarelli interimsafetyanalysisofcancerimmunotherapytrialsnetwork12citn12aphase1studyofpembrolizumabinpatientswithhivandcancer AT cparsons interimsafetyanalysisofcancerimmunotherapytrialsnetwork12citn12aphase1studyofpembrolizumabinpatientswithhivandcancer AT esharon interimsafetyanalysisofcancerimmunotherapytrialsnetwork12citn12aphase1studyofpembrolizumabinpatientswithhivandcancer AT awidell interimsafetyanalysisofcancerimmunotherapytrialsnetwork12citn12aphase1studyofpembrolizumabinpatientswithhivandcancer AT ryarchoan interimsafetyanalysisofcancerimmunotherapytrialsnetwork12citn12aphase1studyofpembrolizumabinpatientswithhivandcancer |